Literature DB >> 20975823

Duloxetine withdrawal seizure.

Abdul Qadir1, Naveed Haider.   

Abstract

Entities:  

Year:  2006        PMID： 20975823      PMCID： PMC2963463     

Source DB:  PubMed          Journal:  Psychiatry (Edgmont)        ISSN： 1550-5952


× No keyword cloud information.
  10 in total

1.  Synergistic benefits of serotonin and noradrenaline reuptake inhibition.

Authors:  J C Nelson
Journal:  Depress Anxiety       Date:  1998       Impact factor: 6.505

Review 2.  Duloxetine for management of stress urinary incontinence.

Authors:  David R P Guay
Journal:  Am J Geriatr Pharmacother       Date:  2005-03

Review 3.  Safety and adverse event profile of duloxetine.

Authors:  Joachim F Wernicke; James Gahimer; Ilker Yalcin; Meghan Wulster-Radcliffe; Lars Viktrup
Journal:  Expert Opin Drug Saf       Date:  2005-11       Impact factor: 4.250

4.  Duloxetine vs. placebo in patients with painful diabetic neuropathy.

Authors:  David J Goldstein; Yili Lu; Michael J Detke; Thomas C Lee; Smriti Iyengar
Journal:  Pain       Date:  2005-07       Impact factor: 6.961

Review 5.  Awareness, diagnosis, and treatment of depression.

Authors:  L S Goldman; N H Nielsen; H C Champion
Journal:  J Gen Intern Med       Date:  1999-09       Impact factor: 5.128

6.  Duloxetine 60 mg once-daily in the treatment of painful physical symptoms in patients with major depressive disorder.

Authors:  Stephen K Brannan; Craig H Mallinckrodt; Eileen B Brown; Madelaine M Wohlreich; John G Watkin; Alan F Schatzberg
Journal:  J Psychiatr Res       Date:  2005-01       Impact factor: 4.791

Review 7.  The National Depressive and Manic-Depressive Association consensus statement on the undertreatment of depression.

Authors:  R M Hirschfeld; M B Keller; S Panico; B S Arons; D Barlow; F Davidoff; J Endicott; J Froom; M Goldstein; J M Gorman; R G Marek; T A Maurer; R Meyer; K Phillips; J Ross; T L Schwenk; S S Sharfstein; M E Thase; R J Wyatt
Journal:  JAMA       Date:  1997 Jan 22-29       Impact factor: 56.272

8.  Duloxetine in the treatment of depression: a double-blind placebo-controlled comparison with paroxetine.

Authors:  David J Goldstein; Yili Lu; Michael J Detke; Curtis Wiltse; Craig Mallinckrodt; Mark A Demitrack
Journal:  J Clin Psychopharmacol       Date:  2004-08       Impact factor: 3.153

9.  Venlafaxine extended release in the treatment of painful diabetic neuropathy: a double-blind, placebo-controlled study.

Authors:  Michael C Rowbotham; Veeraindar Goli; Nadia R Kunz; Dean Lei
Journal:  Pain       Date:  2004-08       Impact factor: 6.961

10.  Prevalence, nature, and comorbidity of depressive disorders in primary care.

Authors:  J C Coyne; S Fechner-Bates; T L Schwenk
Journal:  Gen Hosp Psychiatry       Date:  1994-07       Impact factor: 3.238
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.